In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Series C lands $20mm for Atlas Genetics

Executive Summary

Infectious disease diagnostics developer Atlas Genetics Ltd. closed a $20mm Series C round from first-time backer RMI Partners (part of RusnanoMedInvest) and returning investors Novartis Venture Funds, Consort Medical, Johnson & Johnson Development Corp., Life Sciences Partners, BB Biotech Ventures, and South West Ventures Fund. Proceeds will help launch its io chlamydia test in Europe, initiate clinical development of the system in the US, and expand the diagnostic to include other indications.
Deal Industry
  • In Vitro Diagnostics
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies